mProX™ Human CD70 Stable Cell Line

Product Information

Target Family

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;HCC44;H23

Target Classification

CD Cell Lines

Target Research Area

Cancer Research;Infectious Research

Related Diseases

Lymphoproliferative Syndrome 3; Lymphoma

Gene ID

Human:970

UniProt ID

Human:P32970

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

CD70 is a protein that has been studied in various applications. In clear cell renal cell carcinoma (ccRCC), the gene LINC00887 activates CD70 through the recruitment of SPI1, leading to malignant progression and cell stemness, while inhibiting T-cell chemotaxis. This suggests that targeting the LINC00887-SPI1-CD70 regulatory axis could be a potential breakthrough for treating ccRCC. In Santa Ines sheep, CD70 is associated with resistance to gastrointestinal nematodes, and its activation is linked to pathways and genes involved in the immune system and inflammatory response. In cancer treatment, a high-affinity humanized antibody called IMM40H targets CD70, eliminating tumors through Fc-mediated effector functions and interrupting CD70/CD27 signaling. In HIV infection, CD70 is involved in the differentiation of proinflammatory Th1/17/22/GM lymphocytes, which are associated with disease progression and immune reconstitution. Finally, in the context of solid tumors, CD70-specific CAR T cells have been studied using a bio-conjugated liquid-like solid medium, providing insights into CAR T cell function, immune trafficking, and infiltration in the tumor microenvironment.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human CD70 Stable Cell Line (S01YF-1023-PY230). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Alex Jones (Verified Customer)

How effective are CD70-targeted therapies in cancer treatment? Apr 04 2023

chat Patrick Liam (Creative Biolabs Scientific Support)

CD70-targeted therapies, including CAR T cells and antibody-drug conjugates, have shown promising results in treating cancers like renal cell carcinoma and acute myeloid leukemia. Apr 04 2023

chat Jordan Davis (Verified Customer)

What role does CD70 play in tumor microenvironment and metastasis? May 20 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

CD70 is involved in tumor invasion and metastasis, particularly in melanoma, by activating pathways that contribute to cancer cell aggressiveness. May 20 2021

Published Data

Fig.1 Knockdown of CD70 in lung cancer cell lines.

The assessment of protein expression of CD70, EMT-transcription factors, and effectors of apoptosis was conducted via immunoblotting in HCC44 and H23 cells, which had been transfected with siRNA targeting CD70 (siCD70) or a control siRNA (siCtrl) for a duration of 96 hours.

Ref: Ortiz-Cuaran, Sandra, et al. "Epithelial-to-mesenchymal transition promotes immune escape by inducing CD70 in non-small cell lung cancer." European Journal of Cancer 169 (2022): 106-122.

Pubmed: 35550950

DOI: 10.1016/j.ejca.2022.03.038

Research Highlights

Wu, Jinfeng. et al. "LINC00887 regulates malignant progression and T-cell chemotaxis in clear cell renal cell carcinoma by activating CD70 via recruitment of SPI1." Gene, 2023.
Several articles have mentioned the involvement of LINC00887 in various cancers such as nasopharyngeal carcinoma, lung cancer, and glioma. However, the specific mechanism by which LINC00887 contributes to the malignant progression of clear cell renal cell carcinoma (ccRCC) remains unclear. This study focuses on investigating the role of LINC00887 in ccRCC malignant progression.
Wu, Jinfeng. et al. "LINC00887 regulates malignant progression and T-cell chemotaxis in clear cell renal cell carcinoma by activating CD70 via recruitment of SPI1." Gene, 2023.
Pubmed: 37858743 DOI: 10.1016/j.gene.2023.147910

Bonvino Stafuzza, Nedenia. et al. "Weighted single-step genome-wide association study and functional enrichment analyses for gastrointestinal nematode resistance traits in Santa Ines sheep." Veterinary parasitology, 2023.
In pursuit of understanding the genetic basis of gastrointestinal nematode resistance in Santa Ines sheep, a comprehensive study was conducted. The dataset consisted of 5529 records from 1703 naturally infected animals, with 37,511 SNPs from 589 animals remaining after rigorous genomic data quality control. Utilizing a weighted single-step approach for genome-wide association analysis, the study identified 20, 22, 21, and 19 genomic regions contributing significantly to fecal egg counts (FEC), Famacha© (FAM), packed cell volume (PCV), and total plasma protein (TPP), respectively. Furthermore, within these regions, a total of 81, 122, 106, and 101 protein-coding genes were found to be associated with FEC, FAM, PCV, and TPP, respectively. Notably, these genes encompassed immune system and inflammatory response functions, including ADCY9, ADRB2, BRAF, CADM1, CCL20, CD70, CREBBP, FNBP1, HTR4, IL16, IL22, IL26, MAPK8, NDFIP1, NLRC3, PAK5, PLCB1, PLCB4, ROCK1, TEK, TNFRSF12A, and VAV1. In addition, functional enrichment analysis using the DAVID tool unveiled several significant pathways and Gene Ontology terms linked to gastrointestinal nematode resistance in Santa Ines sheep, including the chemokine signaling pathway (oas04062), cAMP signaling pathway (oas04024), cGMP-PKG signaling pathway (Oas04022), platelet activation (Oas04611), Rap1 signaling pathway (oas04015), and oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705). These findings represent a valuable contribution to advancing our understanding of the genetic underpinnings of gastrointestinal nematode resistance in Santa Ines sheep.
Bonvino Stafuzza, Nedenia. et al. "Weighted single-step genome-wide association study and functional enrichment analyses for gastrointestinal nematode resistance traits in Santa Ines sheep." Veterinary parasitology, 2023.
Pubmed: 37857178 DOI: 10.1016/j.vetpar.2023.110047